Multi-drug resistant gram-negative bacteria (MDR-GNB) present a significant threat to successful antimicrobial chemotherapy. Among MDR-GNB, Acinetobacter baumannii that are resistant to cephalosporins, carbapenems, and quinolones are becoming a global problem. Our analysis of MDR A. baumannii isolates recovered from military medical facilities treating civilian and military personnel injured in Iraq/Kuwait (Operation Iraqi Freedom) and Afghanistan (Operation Enduring Freedom) showed that the Acinetobacter derived cephalosporinase (ADC), OXA-23 and OXA-58 like carbapenemases are the major reasons for ceftazidime and imipenem resistance. We learned that: 1) ADC is a unique cephalosporinase among the class C enzymes; 2) efflux pumps contribute significantly to quinolone resistance; and 3) the regulation of the AdeABC efflux pump is central to the expression of the MDR phenotype in A. baumannii. The pressing challenge is to understand the genetic and amino acid sequence requirements for beta-lactam resistance, kinetic properties and atomic structures of the ADC and OXA carbapenemases, and the contribution of the efflux pump in MDR A. baumannii.
The aims of this proposal are: 1) to determine the atomic structure of the ADC-7 beta-lactamase and to test novel boronic acid and sulfone transition state inhibitors in order to reveal important structure activity relationships that will guide new inhibitor design; 2) to explore the amino acid requirements for imipenem hydrolysis by OXA carbapenemases and to determine the structure of OXA-23; 3) to elucidate the role of quorum sensing and biofilm formation in MDR A. baumannii; and 4) to determine the genetic variability of the regulatory region (adeR-adeS) of the efflux pump (AdeABC) of MDR isolates by DNA sequencing. We will correlate our sequence analysis of adeR-adeS with a rapid automated PCR based electrospray ionization mass spectrometry method linked with base composition analysis that can detect mutations. Accomplishing these goals will achieve an unprecedented understanding of the protein and substrate interactions and genetic properties responsible for the MDR phenotype. This work will also serve as a paradigm for the rapid diagnosis and prediction of novel MDR phenotypes in A. baumannii, form a basis for the evaluation of novel beta-lactams, and show how enzyme drug targets influence substrate affinity and catalysis. ? ? ?
|Nukaga, Michiyoshi; Papp-Wallace, Krisztina M; Hoshino, Tyuji et al. (2018) Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam. Antimicrob Agents Chemother 62:|
|Kanwar, Anubhav; Marshall, Steven H; Perez, Federico et al. (2018) Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemase-Producing Klebsiella pneumoniae. Open Forum Infect Dis 5:ofy054|
|Ghiglione, Barbara; Rodríguez, María Margarita; Curto, Lucrecia et al. (2018) Defining Substrate Specificity in the CTX-M Family: the Role of Asp240 in Ceftazidime Hydrolysis. Antimicrob Agents Chemother 62:|
|Papp-Wallace, Krisztina M; Barnes, Melissa D; Alsop, Jim et al. (2018) Relebactam Is a Potent Inhibitor of the KPC-2 ?-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 62:|
|Tsalik, Ephraim L; Bonomo, Robert A; Fowler Jr, Vance G (2018) New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance. Annu Rev Med 69:379-394|
|Cheng, Zishuo; VanPelt, Jamie; Bergstrom, Alexander et al. (2018) A Noncanonical Metal Center Drives the Activity of the Sediminispirochaeta smaragdinae Metallo-?-lactamase SPS-1. Biochemistry 57:5218-5229|
|VanPelt, Jamie; Shurina, Ben A; Ramelot, Theresa A et al. (2018) 1H, 13C, and 15N backbone resonance assignments for KPC-2, a class A serine-?-lactamase. Biomol NMR Assign :|
|Papp-Wallace, Krisztina M; Nguyen, Nhu Q; Jacobs, Michael R et al. (2018) Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using ?-Lactamase Inhibitors and ?-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem 61:4067-4086|
|Ju, Lin-Cheng; Cheng, Zishuo; Fast, Walter et al. (2018) The Continuing Challenge of Metallo-?-Lactamase Inhibition: Mechanism Matters. Trends Pharmacol Sci 39:635-647|
|Bergstrom, Alexander; Katko, Andrew; Adkins, Zach et al. (2018) Probing the Interaction of Aspergillomarasmine A with Metallo-?-lactamases NDM-1, VIM-2, and IMP-7. ACS Infect Dis 4:135-145|
Showing the most recent 10 out of 183 publications